LifeScan
| Industry | Medical devices |
|---|---|
| Founded | 1981; 44 years ago (1981) |
| Headquarters | |
Area served | Global |
| Revenue | US1ドル.5 billion (2017)[1] |
Number of employees | 2,400(2020)[2] |
| Parent | Platinum Equity |
LifeScan, Inc. is a diagnostic systems manufacturer with products focusing on the diabetes market, specifically blood glucose monitoring systems. Corporate headquarters in Malvern, Pennsylvania.
History
[edit ]LifeScan was established in 1981.[3] It was acquired by Johnson & Johnson (J&J) in 1986,[2] [4] and in June 2018, J&J agreed to sell LifeScan to Platinum Equity as part of its strategic exit from the diabetes device market, accepting an offer originally tendered in March 2018.[1] The divestiture completed in October 2018.[1] [5]
LifeScan manufactures and markets the OneTouch Ultra and OneTouch Verio families of products for home use.[1] The company philosophy is to "create a world without limits for people with diabetes." During its existence, LifeScan revolutionized blood glucose monitoring by introduction of its "One Touch" systems. Originally, the measurement was made using a test strip which changed color depending on the glucose content of a blood sample, and LifeScan rose to become the world-leading producer of such systems in the early 1990s. Later, the measurement technology was changed to electrochemistry, but LifeScan maintained a leading position in the industry.
LifeScan has facilities in Inverness, Scotland; Burnaby, British Columbia, Canada; and Cabo Rojo, Puerto Rico. Animas Corporation of West Chester, Pennsylvania, which produced insulin pumps for people with diabetes, was acquired by Johnson & Johnson in 2006 and now closed, reported to LifeScan.
LifeScan, which employed 2400 people as of early 2018, was the central part of J&J's diabetes device business.[2] J&J announced plans to exit from the diabetes device market in 2017, including divesting LifeScan.[2] In January 2018, there were reports of Chinese investors expressing interest in purchasing the company for US3ドル to 4 billion, while in March, Platinum Equity offered the far smaller sum of US2ドル.1 billion for the unit.[2] [6]
On July 15, 2025, LifeScan filed for Chapter 11 bankruptcy protection as part of a plan to be taken over by its creditors. The company listed assets and liabilities between 1ドル billion and 10ドル billion.[7]
References
[edit ]- ^ a b c d Nawrat, Allie (June 15, 2018). "Johnson & Johnson sells LifeScan to Platinum Equity". Pharmaceutical Technology. Verdict Media Limited. Retrieved June 16, 2018.
- ^ a b c d e Panchadar, Arjun (16 March 2018). "Johnson & Johnson nears diabetes device exit with 2ドル.1 billion LifeScan sale". Reuters. Additional reporting by Caroline Humer and Munsif Vengattil; S D'Souza, P Berlowitz (editors). Retrieved 17 March 2018.
- ^ "LifeScan Inc - Company Profile and News". Bloomberg.com. Retrieved 30 April 2024.
- ^ About Us | LifeScan, Inc." LifeScan. Retrieved on September 18, 2014.
- ^ LaVito, Angelica (October 16, 2018). "Johnson & Johnson beats expectations as cancer drugs, new baby care products help boost sales". CNBC .
- ^ "Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc". Content Lab - U.S. 16 March 2018.
- ^ Ma, Dorothy (July 12, 2025). "Platinum-Backed LifeScan Files Bankruptcy to Hand Over Control". Bloomberg. Retrieved July 15, 2025.
External links
[edit ]- Johnson & Johnson subsidiaries
- Diabetes organizations
- Medical technology companies of the United Kingdom
- Companies established in 1981
- 1986 mergers and acquisitions
- 2018 mergers and acquisitions
- Diabetes-related supplies and medical equipment
- Management of diabetes
- Companies that filed for Chapter 11 bankruptcy in 2025